Cost Estimates Related to COVID-19 Treatment in Indonesia: What Should be Concerned?

Abstract

Coronavirus Disease-2019 (COVID-19) is a pandemic disease in all over the world caused by SARS-COV-2 virus. This disease also spread all over Indonesia. The cost of treating People Under Surveillance and Patient under Monitoring, also confirmed patient of COVID-19 will be financed by the Indonesian Government. This research aimed to identify the estimated cost for treating the Covid-19 patients in Indonesia. The calculation method used top up costs and INA CBGs based on the number of hospitalized positive patients. The data source was COVID-19 data in Central Java and national data. Case growth calculated by doubling time positive cases of COVID-19 in Central Java were 1.7 (range 1.73 – 2.73). Range of days was between 6-8 days. The amount of top up cost for one day treatment refers to Health Ministry of Indonesia Decree Number HK.01.07/MENKES/238/2020 and cost estimation of INACBGs with the severity level II and III. This calculation did not include donations, outpatients and other costs. The result of this study, estimation if patients were treated in ICU for 8 days and non ICU for 7 days, and the rest of inpatients according to INACBs, so the cost of COVID-19 treatment for 14 – 28 days estimated at 75.7-77.3 million rupiah/patient. Whereas if the patient treated in ICU for 14 days and non ICU for 14 days, the rest of inpatient according to INACBs, the cost for COVID-19 treatment estimated at 130.4- 133.2 million rupiah/patient. The COVID-19 treatment is quite expensive and can be a burden for the Government of Indonesia’s budget. In addition, the limited access and health facilities also become an obstacle. Strengthening promotive and preventive efforts are needed to prevent the surge of COVID-19 case. Policies which support strict social and physical distancing are needed so that the interventions become more effective.

Pembiayaan Pasien COVID-19 dan Dampak Keuangan terhadap Rumah Sakit yang Melayani Pasien COVID-19 di Indonesia Analisis Periode Maret 2020 – Desember 2020

“…Biaya penanganan pasien COVID-19 di rumah sakit relatif tinggi, karena memerlukan ruang isolasi khusus, disamping komponen biaya perawatan lain yang mahal seperti antivirus, terapi oksigen dan perawatan intensif dengan ventilator untuk menangani pasien berat dan kritis. (Bartsch et al, 2020;Patria Jati et al, 2020) Seluruh biaya perawatan pasien COVID-19 ditanggung pemerintah sesuai dengan Peraturan Menteri Kesehatan Nomor 59 Tahun 2016 Selama pandemi hampir semua rumah sakit mengalami masalah keuangan walaupun seluruh biaya perawatan pasien COVID-19 ditanggung pemerintah. Hal ini disebabkan sebagian besar masyarakat menahan diri untuk memeriksakan diri ke rumah sakit karena khawatir akan tertular COVID-19 di fasilitas pelayanan kesehatan.…”

Analysis of Ideal Cost Service Claims for Hospitalized Covid-19 Patient

“…It also demonstrates that hospital management can apply efficiency efforts without sacrificing the quality of patient service (Jati et al, 2020). This result is proven with no negative deficit in patients found from the entire sample.…”

Cost-effectiveness and Side Effects of Using Heparin and Enoxaparin as a Treatment for COVID-19-associated Coagulopathy

“…Indonesia Case Based Groups or INACBGs noted that the average cost needed to treat COVID-19 patients who were treated in the ICU and non-ICU for 14 days ranged from US$8,666 to 8,886, while for patients treated in non-ICU for seven days and in the ICU for eight days, it costs US$5,000–5,100. 12 Developing a pharmacoeconomic analysis is one method for analyzing the cost-effectiveness of the treatments. Given the need for cost-effective comparisons between these two anti-coagulants and the inclusion of the most important clinical criteria to ensure modeling best practices are followed, this research is anticipated to be useful in policy-making.…”